Project Grant R01MH140323
- The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $462,000 on August 14, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop a novel spatial transcriptomics platform and investigate RNA-binding protein function in human neurons as it relates to schizophrenia risk. The award funds two primary aims. The first develops a spatial RNA-protein interactome MERFISH (SPRIM) platform to visualize endogenous RNA-protein interactions at...
- The National Institute of Mental Health awarded Cold Spring Harbor Laboratory $528,000 on June 19, 2026, under the Mental Health Research Grants program (CFDA 93.242) to support developmental characterization of synapses between neurons and oligodendrocyte precursor cells. The funded research investigates structural, functional, and molecular properties of neuron-OPC synapses, a class of synaptic connections that remain poorly understood despite evidence that oligodendrocyte precursor cells...
- The National Institute of Mental Health awarded the University of Pittsburgh $751,430 on August 4, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a multi-omic atlas of dendritic spine morphometry across postnatal development in neurotypical and autism spectrum disorder subjects. The research interrogates trajectories of synaptic protein network features—protein expression, synaptosome levels, and phosphorylation—in the prefrontal cortex and primary visual...
- The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $701,763 on April 24, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate the role of the ventral CA1 hippocampal subregion in valence-associated social memories and emotional memory processing. The five-year project, which runs through January 31, 2031, will uncover the neural circuits mediating positive and negative social memories, identify hippocampal cell types supporting...
- The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $169,701 on September 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct multiomic and spatial profiling of hippocampal development and subfield specification. The research deploys single-nucleus RNA sequencing, single-nucleus ATAC sequencing, and spatial sequencing on human fetal hippocampal and neocortical tissue (gestational weeks 16–24) and human induced pluripotent stem...
- The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $839,815 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct a clinical and translational research project investigating neuroimmune mechanisms of depression and anhedonia. The project tests the hypothesis that heightened peripheral immune function and increased blood-brain barrier permeability contribute to major depressive disorder and anhedonia severity. Work is...
- The National Institute of Mental Health awarded Yale University $157,388 on July 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to functionally characterize somatic mosaic variants in the brains of patients with schizophrenia and autism and determine their causal roles in neurodevelopmental disease. The funded work applies massively parallel reporter assays, CRISPR technology, and human induced pluripotent stem cell-derived neural progenitor cells and post-mitotic neurons...
- The National Institute of Mental Health awarded Weill Medical College of Cornell University $800,667 on March 10, 2026, under the Mental Health Research Grants program (CFDA 93.242) to investigate transcriptional control by autism-associated H3K9 methylation regulators during human neurogenesis. The recipient will combine targeted protein depletion with directed differentiation of human pluripotent stem cells to dissect gene regulatory functions of the autism-associated chromatin repressor EHMT1...
- The National Institute of Mental Health awarded The Trustees of Columbia University in the City of New York $534,191 on April 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to develop robust fine-mapping tools for genetic discovery in neuropsychiatric traits using deep phenotype data from diverse populations. The project addresses the challenge of understanding genetic causes of complex neuropsychiatric conditions including autism spectrum disorders, bipolar disorder, and...
- The National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), awarded a $431,750 Project Grant to Rutgers, The State University of New Jersey. The award will fund research into the molecular mechanisms behind the sex-specific deficits observed in neurodevelopmental disorders such as autism spectrum disorder (ASD). The research aims to investigate how hormones and sex-specific signaling interact in the development of behavioral deficits, using...
The National Institute of Mental Health awarded Icahn School of Medicine at Mount Sinai $763,265 on August 18, 2026, under the Mental Health Research Grants program (CFDA 93.242) to characterize splicing and isoform dysregulation in autism spectrum disorder at cellular resolution. The recipient will profile postmortem prefrontal cortex brain tissue from 74 individuals with ASD and 74 neurotypical controls across the lifespan, from childhood to adulthood, using long-read multiplexed arrays isoform sequencing and the IsoPropeller analysis framework to resolve complete isoform structure and quantitate cell-type-specific isoform expression at single-nucleus resolution. The research will identify significant changes in isoform abundance and usage between ASD and controls and delineate cell-type and age-dependent expression patterns. The recipient will integrate these isoform data with existing genotypes from the same subjects to conduct allelic-isoform analyses and map regulatory genetic effects on isoform expression. The work addresses a gap in understanding isoform dysregulation contribution to psychiatric disorders, as changes in isoform expression rather than overall changes in gene expression show the largest effect sizes and genetic enrichments in ASD compared to neurotypical controls. Performance occurs in New York. The award period runs through April 30, 2031.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $763.3k | 8/20/26 |